Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know.

Amneal beat analysts’ revenue expectations last quarter, reporting revenues of $814.3 million, up 11.5% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates but full-year revenue guidance missing analysts’ expectations significantly.

Is Amneal a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Amneal’s revenue to grow 3.3% year on year, slowing from the 5.5% increase it recorded in the same quarter last year.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amneal has missed Wall Street’s revenue estimates multiple times over the last two years.

With Amneal being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 6.4% on average over the last month. Amneal is up 1.8% during the same time .

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.